
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals, Inc. is projected to see significant revenue growth associated with its product Khindivi, which is expected to peak at $28 million by 2030, up from $3 million in 2025. The company's probability of launching Khindivi has been raised to 100%, with expectations that its launch will occur in June rather than the previously anticipated second quarter of 2025, reflecting an increased confidence in its market penetration potential. Additionally, Eton's strong track record in commercial execution suggests that 2025 could be a pivotal year for revenue growth, bolstering a positive outlook for the company's financial performance.
Bears say
Eton Pharmaceuticals faces a challenging outlook due to the assumptions of an 11% discount rate and a low terminal growth rate of 2%, which may limit future profitability and growth potential. Despite a modest increase in the projected price target from $33 to $35 per diluted share, the financial projections indicate that the growth metrics remain subdued. This combination of high discounting and low growth expectations raises concerns about the sustainability of Eton Pharmaceuticals's financial performance in the competitive specialty pharmaceutical market.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares